Conference Coverage

Updates from the GENEr8-1 Trial

Updates on SPK-8011

Phase 3 HOPE-B Trial of etranacogene dezaparvovec in Severe/Moderately Severe Hemophilia B

Residual Burden of Liver Disease After HCV-clearance in Hemophilia: A Word of Caution in the Era of Gene Therapy

Efficacy and Safety of Fidanacogene Elaparvovec in Adults With Moderately Severe or Severe Hemophilia B: Results From the Phase 3 BENEGENE-2 Gene Therapy Trial

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL